comparemela.com

Latest Breaking News On - Francesco passamonti - Page 1 : comparemela.com

Bristol Myers Squibb to Present Data at ASCO & EHA from More Than 130 Studies Across 25 Diseases Supporting Expansion into New Indications, Demonstrating Long-Term Survival, and Highlighting Novel Modalities and Research Platforms

Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data across its oncology and hematology portfolio at the upcoming 2024 American Society of Clinical Oncology (ASCO) Annual Meeting

United statesSouth koreaPushkar muthaMariat bourlonTycel jovelle phillipsTony mokLin wangPeter robert galleCharlene mantiaMarc hoffmannEric christensonSuzanne trudelManali kirtikumar kamdarGuillermo garcia maneroMartin reckTina cascone

Bristol Myers Squibb s First Disclosures and New Data at ASH 2023 Highlight Company s Leadership and Progress in Cell Therapy, Targeted Protein Degradation and Novel Approaches in Hematology -November 02, 2023 at 11:35 am EDT

First presentation of results from primary analysis of Phase 2 TRANSCEND FL study evaluating second-line treatment with Breyanzi® in relapsed or refractory follicular lymphoma demonstrate its.

United statesSan diegoSikander ailawadhiFrancesco passamontiLisocabtagene maraleucelGuillaume cartronRavi vijMaroof hasanMark kaplanRachid bazHemophagocytic lymphohistiocytosisDanny jeyarajuSheida hayatiSusan balSamit hirawatFranck morschhauser

Pelabresib Provides Clinical Benefit in Hydroxyurea-Refractory or Intolerant High-Risk Essential Thrombocythemia

Treatment with pelabresib monotherapy led to a 60% confirmed complete or partial hematologic response at any time without incurring grade 4 or 5 treatment-related adverse effects in patients with high-risk essential thrombocythemia refractory or intolerant to hydroxyurea.

Francesco passamontiUniversity of insubria vareseUniversity hospital of vareseDivision of hematologyDynamic international prognostic scoring systemUniversity hospitalPelabresib monotherapyPatients with high risk essential thrombocythemia refractory or intolerant to hydroxyureaPhase 2 manifest trialArm 42023 eha congressComplete or partial hematologic response

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

First disclosure from Phase 3 COMMANDS study, selected for both ASCO’s official press program and EHA’s plenary session, highlights potential of Reblozyl as first-line treatment of. | May 11, 2023

United statesSouth koreaAndrew weiBartl scottJean marie michotLorettaj nastoupilNizarj bahlisMitsuho imaiJohn mascarenhasAmit vermaKevin joseph harringtonDavid paul carboneHemophagocytic lymphohistiocytosisHeinz josef lenzFarrukh awanHusseina tawbi

Bristol Myers Squibb to Highlight Diversified Approaches and Commitment to Improving Outcomes for Patients with Cancer and Serious Blood Disorders at ASCO, EHA and ICML 2023

11.05.2023 - Bristol Myers Squibb (NYSE: BMY) today announced the presentation of data at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting, the European Hematology Association (EHA) Congress, and the International Conference on Malignant .

United statesSouth koreaAmit vermaSaloman manierAlit taherAndrew weiHemophagocytic lymphohistiocytosisBartl scottJonathan spicerPaul david harker murrayHaifa kathrin al aliJavier munozJavidj moslehiKrina patelFarrukh awanRafat abonour

vimarsana © 2020. All Rights Reserved.